Clone:
REA765
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC, MICS, IF, IHC, MC
Alternative names:
CDw137, TNFRSF9, ILA, Ly-63, 4-1BB

Extended validation for CD137 Antibody, anti-human, REAfinity™

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with REA765
4B4-1++
Cells were incubated with an excess of purified unconjugated CD137 (REA765) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD137. Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD137 antibodies and with a suitable counterstaining. As a control, CD137 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD137. Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD137 antibodies and with a suitable counterstaining. As a control, CD137 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD137. Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD137 antibodies and with a suitable counterstaining. As a control, CD137 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD137. Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD137 antibodies and with a suitable counterstaining. As a control, CD137 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD137. Human peripheral blood mononuclear cells (PBMCs) stimulated with CD3/CD28 antibodies (T Cell TransAct™) for 16 hours were stained with CD137 antibodies and with a suitable counterstaining. As a control, CD137 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. CD4+ cells were pregated for the analysis. Cell debris and cell doublets were excluded from the analysis based on scatter signals. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD137 (REA765). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD137 (REA765). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD137 (REA765). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD137 Antibody, anti-human, REAfinity™

Overview

Clone REA765 recognizes the human CD137 antigen, a 30 kDa glycoprotein of the tumor necrosis factor (TNF) receptor superfamily, a group of cytokines that can cause cell death (apoptosis). CD137 is mainly expressed on activated CD4
+
and CD8
+
T cells, activated B cells, and natural killer cells, but can also be found on resting monocytes and dendritic cells. As a costimulatory molecule it is involved in the activation and survival of CD4
+
or CD8
+
T cells and NK cells. CD137 has been described to be a suitable marker for antigen-specific activation of human CD8
+
T cells, as it is not expressed on resting CD8
+
T cells and its expression is reliably induced after 24 hours of stimulation.
Additional information: Clone REA765 displays negligible binding to Fc receptors.

Alternative names

CDw137, TNFRSF9, ILA, Ly-63, 4-1BB

Detailed product information

Technical specifications

CloneREA765
Clonalitymonoclonal
Isotyperecombinant human IgG1
Isotype controlREA Control Antibody (S), human IgG1
Hostcell line
Type of antibodyPrimary antibodies, Recombinant antibodies
Specieshuman, non-human primate
Cross-reactivity
cynomolgus monkey (
Macaca fascicularis
)
,
rhesus monkey (
Macaca mulatta
)
AntigenCD137
Alternative names of antigenCDw137, TNFRSF9, ILA, Ly-63, 4-1BB
Molecular mass of antigen [kDa]25
Distribution of antigenB cells, T cells, dendritic cells, epithelial cells, macrophages, monocytes, fibroblasts, lymphocytes
Entrez Gene ID3604
RRIDAB_2654989, AB_2654990, AB_2654991, AB_2654992, AB_2654993, AB_2654994, AB_2819661, AB_2654984, AB_2654985, AB_2654986, AB_2654987, AB_2654988, AB_2654983

References for CD137 Antibody, anti-human, REAfinity™

Publications

  1. Alderson, M. R. et al. (1994) Molecular and biological characterization of human 4-1BB and its ligand. Eur. J. Immunol. 24(9): 2219-2227
  2. Wolfl, M. et al. (2007)
    Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8
    +
    T cells responding to antigen without requiring knowledge of epitope specificities.
    Blood 110: 201-210

Related products for
CD137 Antibody, anti-human, REAfinity™

3 products available